JP2013545761A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545761A5
JP2013545761A5 JP2013541060A JP2013541060A JP2013545761A5 JP 2013545761 A5 JP2013545761 A5 JP 2013545761A5 JP 2013541060 A JP2013541060 A JP 2013541060A JP 2013541060 A JP2013541060 A JP 2013541060A JP 2013545761 A5 JP2013545761 A5 JP 2013545761A5
Authority
JP
Japan
Prior art keywords
seq
vaccine
vaccine formulation
composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013541060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545761A (ja
JP6055776B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/062120 external-priority patent/WO2012074881A2/en
Publication of JP2013545761A publication Critical patent/JP2013545761A/ja
Publication of JP2013545761A5 publication Critical patent/JP2013545761A5/ja
Application granted granted Critical
Publication of JP6055776B2 publication Critical patent/JP6055776B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013541060A 2010-11-24 2011-11-23 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 Expired - Fee Related JP6055776B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41708910P 2010-11-24 2010-11-24
US61/417,089 2010-11-24
PCT/US2011/062120 WO2012074881A2 (en) 2010-11-24 2011-11-23 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (3)

Publication Number Publication Date
JP2013545761A JP2013545761A (ja) 2013-12-26
JP2013545761A5 true JP2013545761A5 (enExample) 2015-01-22
JP6055776B2 JP6055776B2 (ja) 2016-12-27

Family

ID=46172477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541060A Expired - Fee Related JP6055776B2 (ja) 2010-11-24 2011-11-23 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法

Country Status (6)

Country Link
US (1) US9782474B2 (enExample)
EP (1) EP2643014A4 (enExample)
JP (1) JP6055776B2 (enExample)
AU (1) AU2011336894B2 (enExample)
CA (1) CA2856697A1 (enExample)
WO (1) WO2012074881A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2011336894B2 (en) * 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2012340712B2 (en) * 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US10011013B2 (en) * 2015-03-30 2018-07-03 X Development Llc Cloud-based analysis of robotic system component usage
LT3411388T (lt) 2016-02-01 2022-01-10 Simplexia Ab Sutrumpintas herpes simplex viruso 2 glikoproteinas g
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
WO2021015987A1 (en) * 2019-07-19 2021-01-28 Merck Sharp & Dohme Corp. Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
JP3005292B2 (ja) 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH08510918A (ja) 1993-06-08 1996-11-19 アボツト・ラボラトリーズ 単純ヘルペスウィルス２型プロテアーゼ
CA2169748A1 (en) 1993-08-20 1995-03-02 Anthony G. Dilella Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
CA2269754A1 (en) 1996-10-23 1998-04-30 American Home Products Corporation Dna vaccines for herpes simplex virus 1 and 2
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
AU7597998A (en) 1997-06-02 1998-12-21 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
ES2273482T3 (es) 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
JP2002522451A (ja) 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
EP1185662B1 (fr) 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6413518B1 (en) 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
DK1238086T3 (da) 1999-12-17 2006-06-26 Wyeth Corp Vaccine til forögelse af immunreaktioner på herpes simplex virus
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
ATE349533T1 (de) 2000-06-29 2007-01-15 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US20030165819A1 (en) 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
JP2004505113A (ja) 2000-07-27 2004-02-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 単純疱疹ウイルス糖蛋白質ｄを用いた組成物及びそれを用いて免疫応答を抑制する方法
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20020094337A1 (en) 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
US6814969B2 (en) 2001-07-31 2004-11-09 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
AU2002323443A1 (en) 2001-09-04 2003-03-18 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
AU2004274430A1 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2006338570B2 (en) 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
CA2645507A1 (en) 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
CA2663109A1 (en) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Hsv-1 and hsv-2 vaccines and methods of use thereof
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
WO2009006680A1 (en) 2007-07-06 2009-01-15 Sydney West Area Health Service Epitopes of herpes simplex virus
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010078027A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
CA2754592A1 (en) 2009-03-09 2010-09-16 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
US20130195961A1 (en) 2010-03-09 2013-08-01 Kejian Yang Novel mucosal vaccination approach for herpes simplex virus type-2
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
AU2011336894B2 (en) * 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response

Similar Documents

Publication Publication Date Title
Vasireddy et al. Review of COVID-19 vaccines approved in the United States of America for emergency use
JP2013545761A5 (enExample)
JP7792339B2 (ja) コロナウイルスワクチン製剤
KR20220154121A (ko) 코로나바이러스 면역원성 조성물 및 이의 용도
CN101616688B (zh) 单纯疱疹病毒联合亚单位疫苗及其使用方法
JP5771605B2 (ja) 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法
US20200282047A1 (en) Epstein-barr virus vaccines
EP1858917B1 (en) Varicella zoster virus vaccine
JP2012527486A5 (enExample)
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
JP2024545152A (ja) 単純ヘルペスウイルスｍＲＮＡワクチン
ES3050936T3 (en) Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
CN113454102A (zh) 非洲猪瘟疫苗
JP6676661B2 (ja) ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物
Ludlow Respiratory syncytial virus infection in the modern era
EP2172488A1 (en) Material with immunogenicity
AU2021290231A1 (en) Arthrogenic alphavirus vaccine
US20240156951A1 (en) Vaccine compositions and methods for treating hsv
JP7317796B2 (ja) 呼吸器疾患を治療するための方法および組成物
CN116688110A (zh) 犬特应性皮炎的治疗
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列，包含彼之載體，及其用途
JP2014534262A5 (enExample)
US20230192777A1 (en) Epitopic vaccine for african swine fever virus
CN118119646A (zh) 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用
US20200368320A1 (en) Compositions including il-18 and il-22 and their use in anti-viral therapies